Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 12/20 | 0.50 |
| ▸ | FAAH | O00519 | 8/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638842 | 1.00 | MGLL (0.50) | MGLLFAAHCNR1JAK3GPR119 | |
| SCHEMBL20585938 | 0.80 | MGLL (0.44) | MGLLFAAHCNR1 | |
| SCHEMBL20585941 | 0.80 | MGLL (0.44) | MGLLFAAHCNR1 | |
| SCHEMBL20585945 | 0.80 | MGLL (0.44) | MGLLFAAHCNR1 | |
| SCHEMBL29570144 | 0.80 | MGLL (0.71) | MGLLFAAHCNR1 | |
| SCHEMBL18418143 | 0.80 | MGLL (0.71) | MGLLFAAHCNR1 | |
| SCHEMBL25731561 | 0.80 | MGLL (0.54) | MGLLGPR119USP30 | |
| SCHEMBL25731609 | 0.79 | GPR119 (0.50) | MGLLGPR119NAMPT | |
| SCHEMBL25731598 | 0.79 | MGLL (0.53) | MGLLGPR119USP30 | |
| SCHEMBL18418170 | 0.77 | JAK3 (0.43) | JAK3GPR119SSTR4NR1H2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352342-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10752610-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-10329278-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | MGLL 1924/4885FAAH 1960/4885CNR1 25/4885 |
| US-11352342-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MGLL 1924/4885FAAH 1960/4885CNR1 25/4885 |
| US-10329278-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MGLL 1949/4885FAAH 2054/4885CNR1 32/4885 |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | MGLL 1924/4885FAAH 1960/4885CNR1 25/4885 |
| US-10752610-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MGLL 1924/4885FAAH 1960/4885CNR1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.